Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-02-14

Clinical Trial Update: A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures [Phase 3]

View source ↗

Summary

Open-label extension study of ganaxolone in drug-resistant partial-onset seizures; terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ganaxolone (ganaxolone)

Snippet

Sponsor: Marinus Pharmaceuticals | Conditions: Drug Resistant Partial Onset Seizure | Phase 3 | Status: TERMINATED | Results posted: 2023-02-14